NASDAQ:XNCR Xencor Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Xencor, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $28.86 +1.49 (+5.44%) (As of 07/1/2022 12:00 AM ET) Add Compare Share Today's Range$27.22▼$29.0750-Day Range$19.74▼$28.8652-Week Range$19.35▼$43.61Volume411,605 shsAverage Volume364,134 shsMarket Capitalization$1.72 billionP/E Ratio16.21Dividend YieldN/APrice Target$52.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Xencor Stock Forecast (MarketRank)Analyst RatingBuy3.00 Rating ScoreUpside/Downside81.3% Upside$52.33 Price TargetShort InterestBearish5.36% of Float Sold ShortDividend StrengthN/ASustainability-2.24Upright™ Environmental ScoreNews Sentiment0.45Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.62) to ($2.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.28 out of 5 starsMedical Sector321st out of 1,429 stocksPharmaceutical Preparations Industry131st out of 682 stocks 3.5 Analyst's Opinion Consensus RatingXencor has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $52.33, Xencor has a forecasted upside of 81.3% from its current price of $28.86.Amount of Analyst CoverageXencor has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.36% of the float of Xencor has been sold short.Short Interest Ratio / Days to CoverXencor has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Xencor has recently decreased by 0.67%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldXencor does not currently pay a dividend.Dividend GrowthXencor does not have a long track record of dividend growth. Previous Next 3.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreXencor has received a 53.56% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for infectious diseases", "Tafasitamab", and "Ravulizumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Xencor is -2.24. Previous Next 2.5 News and Social Media Coverage News SentimentXencor has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Xencor this week, compared to 3 articles on an average week.Search Interest2 people have searched for XNCR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xencor insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.23% of the stock of Xencor is held by insiders.Percentage Held by Institutions98.43% of the stock of Xencor is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Xencor are expected to decrease in the coming year, from ($1.62) to ($2.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xencor is 16.21, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 47.03.Price to Earnings Ratio vs. SectorThe P/E ratio of Xencor is 16.21, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 41.94.Price to Book Value per Share RatioXencor has a P/B Ratio of 2.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive XNCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter. Email Address About Xencor (NASDAQ:XNCR)Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. Its product candidates include Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. In addition, it is developing VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. Further, the company is developing AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.Read More XNCR Stock News HeadlinesJuly 1, 2022 | realmoney.thestreet.comShares of Xencor Could Be Bought on a 50% Correction - RealMoneyJuly 1, 2022 | finance.yahoo.comShares of Xencor Could Be Bought on a 50% CorrectionJune 23, 2022 | finance.yahoo.comOncorus Appoints Douglas Fambrough to Board of Directors - Yahoo FinanceJune 21, 2022 | americanbankingnews.comXencor (NASDAQ:XNCR) Downgraded by StockNews.com to "Sell"June 12, 2022 | americanbankingnews.comXencor (NASDAQ:XNCR) Hits New 12-Month Low at $20.75June 10, 2022 | americanbankingnews.comAnalysts Set Expectations for Xencor, Inc.'s FY2023 Earnings (NASDAQ:XNCR)June 8, 2022 | finance.yahoo.comNext-Generation Antibody Market to hit $12.05 Bn, Globally, by 2028 at 11.9% CAGR, says The Insight Partners - Yahoo FinanceJune 3, 2022 | seekingalpha.comXencor: Capital-Efficient Platform Tech Play With A Lot Going OnJune 2, 2022 | nasdaq.comFirst Week of July 15th Options Trading For Xencor (XNCR) - NasdaqMay 28, 2022 | streetinsider.comXencor (XNCR) Reports Dose-Escalation Data from Phase 1 Study of XmAb 104, PD-1 x ICOS Bispecific Antibody - StreetInsider.comMay 26, 2022 | businesswire.comXencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors - Business WireMay 26, 2022 | finance.yahoo.comXencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid TumorsMay 25, 2022 | streetinsider.comInnoCare Announces Approval to Conduct a Phase II Clinical Trial of Tafasitamab in Combination with Lenalidomide in China - StreetInsider.comSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XNCR CUSIPN/A CIK1326732 Webwww.xencor.com Phone(626) 305-5900Fax626-305-0350Employees254Year FoundedN/ACompany Calendar Last Earnings5/05/2022Today7/01/2022Next Earnings (Estimated)8/03/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$52.33 High Stock Price Forecast$60.00 Low Stock Price Forecast$42.00 Forecasted Upside/Downside+81.3%Consensus RatingBuy Rating Score (0-4)3 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$1.779990 Trailing P/E Ratio16.21 Forward P/E RatioN/A P/E GrowthN/ANet Income$82.63 million Net Margins33.28% Pretax Margin33.28% Return on Equity15.74% Return on Assets14.08% Debt Debt-to-Equity RatioN/A Current Ratio8.30 Quick Ratio8.30 Sales & Book Value Annual Sales$275.11 million Price / Sales6.25 Cash Flow$1.71 per share Price / Cash Flow16.83 Book Value$12.54 per share Price / Book2.30Miscellaneous Outstanding Shares59,543,000Free Float57,024,000Market Cap$1.72 billion OptionableOptionable Beta0.81 Xencor Frequently Asked Questions Should I buy or sell Xencor stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Xencor stock. View analyst ratings for Xencor or view top-rated stocks. What is Xencor's stock price forecast for 2022? 8 Wall Street research analysts have issued 1-year price targets for Xencor's stock. Their XNCR stock forecasts range from $42.00 to $60.00. On average, they anticipate Xencor's stock price to reach $52.33 in the next year. This suggests a possible upside of 81.3% from the stock's current price. View analysts' price targets for Xencor or view top-rated stocks among Wall Street analysts. How has Xencor's stock price performed in 2022? Xencor's stock was trading at $40.12 at the start of the year. Since then, XNCR shares have decreased by 28.1% and is now trading at $28.86. View the best growth stocks for 2022 here. When is Xencor's next earnings date? Xencor is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022. View our earnings forecast for Xencor. How were Xencor's earnings last quarter? Xencor, Inc. (NASDAQ:XNCR) announced its quarterly earnings results on Thursday, May, 5th. The biopharmaceutical company reported $0.39 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $1.09. The biopharmaceutical company had revenue of $85.50 million for the quarter, compared to the consensus estimate of $26.17 million. Xencor had a trailing twelve-month return on equity of 15.74% and a net margin of 33.28%. The firm's revenue for the quarter was up 152.2% on a year-over-year basis. During the same period last year, the firm earned ($0.04) EPS. View Xencor's earnings history. Who are Xencor's key executives? Xencor's management team includes the following people: Dr. Bassil I. Dahiyat Ph.D., Co-Founder, CEO, Pres & Director (Age 52, Pay $1.08M)Mr. John J. Kuch, Sr. VP & CFO (Age 63, Pay $648.03k)Dr. John R. Desjarlais, Sr. VP of Research & Chief Scientific Officer (Age 58, Pay $725.03k)Ms. Celia E. Eckert J.D., Sr. VP, Gen. Counsel & Corp. Sec. (Age 49, Pay $600.93k)Dr. Allen S. Yang M.D., Ph.D., Sr. VP & Chief Medical Officer (Age 54, Pay $748.13k)Mr. Charles Liles, Associate Director and Head of Corp. Communications & Investor RelationsMs. Jennifer Sandoz, VP of HRDr. Jeremy Grunstein Ph.D., Sr. VP of Bus. Devel.Mr. Kirk Rosemark RAC, Sr. VP of Regulatory Affairs & Quality Assurance (Age 57) What is Bassil I. Dahiyat's approval rating as Xencor's CEO? 6 employees have rated Xencor CEO Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among Xencor's employees. Who are some of Xencor's key competitors? Some companies that are related to Xencor include Sarepta Therapeutics (SRPT), Perrigo (PRGO), Ionis Pharmaceuticals (IONS), Ascendis Pharma A/S (ASND), Intra-Cellular Therapies (ITCI), Alkermes (ALKS), Apellis Pharmaceuticals (APLS), Hypera (HYPMY), Ultragenyx Pharmaceutical (RARE), Evotec (EVTCY), Mirati Therapeutics (MRTX), Cerevel Therapeutics (CERE), Arrowhead Pharmaceuticals (ARWR), Zai Lab (ZLAB) and Karuna Therapeutics (KRTX). View all of XNCR's competitors. What other stocks do shareholders of Xencor own? Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), Intel (INTC), AMC Entertainment (AMC) and Ciena (CIEN). What is Xencor's stock symbol? Xencor trades on the NASDAQ under the ticker symbol "XNCR." How do I buy shares of Xencor? Shares of XNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Xencor's stock price today? One share of XNCR stock can currently be purchased for approximately $28.86. How much money does Xencor make? Xencor (NASDAQ:XNCR) has a market capitalization of $1.72 billion and generates $275.11 million in revenue each year. The biopharmaceutical company earns $82.63 million in net income (profit) each year or $1.779990 on an earnings per share basis. How many employees does Xencor have? Xencor employs 254 workers across the globe. How can I contact Xencor? Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The official website for Xencor is www.xencor.com. The biopharmaceutical company can be reached via phone at (626) 305-5900, via email at [email protected], or via fax at 626-305-0350. This page (NASDAQ:XNCR) was last updated on 7/1/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here